Interesting Images68Ga-Fibroblast Activation Protein Inhibitor, a Promising Radiopharmaceutical in PET/CT to Detect the Primary and Metastatic Lesions of Chromophobe Renal Cell CarcinomaPang, Yizhen MD∗; Wei, Jihong MD∗; Shang, Qihang MD∗; Zhao, Liang MD†; Chen, Haojun MD, PhD∗Author Information From the ∗Department of Nuclear Medicine & Minnan PET Center, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University †Department of Radiation Oncology, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Teaching Hospital of Fujian Medical University, Xiamen, China. Received for publication October 11, 2020; revision accepted October 26, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Haojun Chen, MD, PhD, 55 Zhenhai Road, Xiamen 361003, China. E-mail: [email protected]. Clinical Nuclear Medicine: February 2021 - Volume 46 - Issue 2 - p 177-179 doi: 10.1097/RLU.0000000000003454 Buy Metrics Abstract 18F-FDG PET/CT was performed to locate the primary lesion in a 71-year-old man with bone metastasis. However, no abnormal 18F-FDG activity likely presenting the primary tumor was observed. 68Ga-fibroblast activation protein inhibitor PET/CT was then performed for further detecting the primary tumor, which showed a higher activity in lesions of bone metastases than 18F-FDG. Additionally, another lesion with intense uptake was observed in the inferior pole of right kidney, likely presenting the primary tumor. A renal biopsy revealed the diagnosis of chromophobe renal cell carcinoma. This case highlighted that 68Ga-fibroblast activation protein inhibitor could be a promising radiopharmaceutical in the diagnosis of renal cell carcinoma. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.